Want to see ANGO full AI Analyst Report?
Top Page
AngioDynamics
(NASDAQ:ANGO)
Select Model
Select Model
Rating:52Neutral
Price Target:
$11.50
▼(-26.70% Downside)
Action:Reiterated
Date:10/09/26
ANGO scores as middling overall: financial performance is improving (revenue rebound, solid gross margin, modestly positive cash flow and a debt-free balance sheet) but the company remains loss-making and equity has trended down. Technical indicators are notably weak with the stock below key moving averages and depressed momentum readings, while valuation is difficult to assess due to a negative P/E and no dividend yield data. The latest earnings call supports the recovery narrative with maintained guidance and better profitability metrics, but continued adjusted-loss guidance and reimbursement/tariff uncertainty temper the outlook.
Positive Factors
Auryon growth and share gains
Auryon’s sustained double-digit growth across hospital and office-based laboratory settings indicates durable adoption and expanding commercial reach. Continued international uptake and share gains can strengthen the MedTech mix, support recurring procedure-related demand, and improve the company’s growth profile over the next several quarters.
Negative Factors
Persistent operating losses
The continued adjusted-loss outlook shows that revenue growth and improved EBITDA have not yet translated into consistent bottom-line profitability. Until earnings turn sustainably positive, the company remains reliant on further operating leverage and execution, limiting the durability of its financial improvement.
Read all positive and negative factors
Positive Factors
Negative Factors
Auryon growth and share gains
Auryon’s sustained double-digit growth across hospital and office-based laboratory settings indicates durable adoption and expanding commercial reach. Continued international uptake and share gains can strengthen the MedTech mix, support recurring procedure-related demand, and improve the company’s growth profile over the next several quarters.
Read all positive factors
AngioDynamics (ANGO) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$515.59M
Dividend YieldN/A
Average Volume (3M)910.88K
Price to Earnings (P/E)―
Beta (1Y)0.17
Revenue Growth8.20%
EPS Growth-0.88%
CountryUS
Employees632
SectorHealthcare
Sector Strength45
IndustryMedical - Instruments & Supplies
Share Statistics
EPS (TTM)-0.79
Shares Outstanding42,054,450
10 Day Avg. Volume1,031,960
30 Day Avg. Volume910,877
Financial Highlights & Ratios
PEG Ratio-2.06
Price to Book (P/B)2.65
Price to Sales (P/S)1.42
P/FCF Ratio891.83
Enterprise Value/Market Cap1.27
Enterprise Value/Revenue2.01
Enterprise Value/Gross Profit3.61
Enterprise Value/Ebitda-66.31
Forecast
1Y Price Target
$19.00Price Target Upside21.10% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.28
Revenue Forecast (FY)$337.70M
AngioDynamics Business Overview & Revenue Model
Company Description
AngioDynamics, Inc. specializes in the development, manufacturing, and commercialization of a diverse array of medical, surgical, and diagnostic instruments. These products are utilized by healthcare professionals to address conditions such as per...
How the Company Makes Money
AngioDynamics makes money primarily by selling medical devices to hospitals, outpatient centers, and other healthcare providers, with revenue generally recognized from product sales (typically upon delivery/transfer of control depending on contrac...
AngioDynamics Earnings Call Summary
Earnings Call Date:Oct 08, 2026
(Q1-2027)
| % Change Since: |
Next Earnings Date:Jan 07, 2027
Earnings Call Sentiment Positive
The call had a strongly positive tone, supported by 6.9% total revenue growth, 13.2% MedTech growth, sustained double-digit Auryon growth, strong AlphaVac and NanoKnife performance, improved profitability, a debt-free balance sheet, and maintained fiscal-year guidance. The principal challenges were the year-over-year AngioVac decline, sequential NanoKnife disposable seasonality, cash usage in Q1, tariff and inflation-related margin factors, an ongoing adjusted loss outlook, and the need for broader NanoKnife reimbursement. Highlights significantly outweighed the lowlights.Positive Updates
CEO Succession Plan Completed
The board completed its search for a successor, and Eric Honer will become President and Chief Executive Officer effective November 2. He brings more than 20 years of medical device and life sciences leadership experience, including roles at Getinge, Abbott Vascular, Becton Dickinson, CareFusion, and Boston Scientific. Jim Clemmer will remain closely involved to support a smooth transition.
Negative Updates
AngioVac Revenue Declines Year Over Year
AngioVac revenue was $7.5 million, representing a 5.9% year-over-year decrease. Management said the business is working through a tougher comparison, although revenue grew 9.1% sequentially and underlying demand remains strong. The company expects AngioVac to return to more normal growth as the year progresses.
Read all updates
Q1-2027 Updates
Positive
Negative
CEO Succession Plan Completed
The board completed its search for a successor, and Eric Honer will become President and Chief Executive Officer effective November 2. He brings more than 20 years of medical device and life sciences leadership experience, including roles at Getinge, Abbott Vascular, Becton Dickinson, CareFusion, and Boston Scientific. Jim Clemmer will remain closely involved to support a smooth transition.
Read all positive updates
Company Guidance
For fiscal 27, AngioDynamics continues to anticipate net sales of $336 million to $341 million, representing growth of between 5% to 6.5% over 2020 revenue of $320.2 million; MedTech net sales are expected to grow 12% to 15% year over year and MedDevice sales to be roughly flat, while gross margin is expected to be in the range of 54% to 55%, adjusted EBITDA in the range of $13 million to $16 million, and adjusted loss per share in the range of $0.29 to $0.24. The company remains on track to generate positive cash flow from operations for the full fiscal year, is targeting approximately 10% of sales for R&D going forward, expects mechanical thrombectomy to continue to grow with AngioVac in the single digit growth and AlphaVac driving that growth, and expects the impact from tariffs to be broadly similar to fiscal 26 based on its current view of the tariff situation, but this remains dynamic and clearly subject to change.AngioDynamics Financial Statement Overview
Summary
Income Statement
38
Negative
Balance Sheet
72
Positive
Cash Flow
46
Neutral
| Breakdown | TTM | May 2026 | May 2025 | May 2024 | May 2023 | May 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 325.38M | 320.17M | 292.50M | 303.91M | 338.75M | 316.22M |
| Gross Profit | 181.07M | 174.89M | 157.71M | 154.70M | 174.25M | 165.73M |
| EBITDA | -9.87M | 488.00K | 1.74M | -6.13M | 12.19M | 11.13M |
| Net Income | -32.94M | -36.74M | -33.99M | -184.35M | -52.44M | -26.55M |
Balance Sheet | ||||||
| Total Assets | 241.93M | 267.16M | 280.14M | 317.67M | 532.64M | 552.75M |
| Cash, Cash Equivalents and Short-Term Investments | 33.97M | 53.86M | 55.89M | 76.06M | 44.62M | 28.82M |
| Total Debt | 10.74M | 0.00 | 10.15M | 4.73M | 64.58M | 33.78M |
| Total Liabilities | 77.97M | 96.34M | 97.17M | 112.08M | 154.34M | 128.26M |
| Stockholders Equity | 163.96M | 170.82M | 182.97M | 205.59M | 378.30M | 424.49M |
Cash Flow | ||||||
| Free Cash Flow | 1.44M | 508.00K | -14.59M | -33.93M | -4.27M | -11.49M |
| Operating Cash Flow | 3.67M | 3.09M | -10.13M | -28.16M | 78.00K | -7.19M |
| Investing Cash Flow | -7.55M | -5.95M | -10.18M | 123.72M | -9.75M | -19.31M |
| Financing Cash Flow | -954.00K | 564.00K | -255.00K | -64.25M | 25.42M | 7.68M |
AngioDynamics Technical Analysis
Negative
15.69
Price Trends
14.41
Negative
14.02
Negative
12.45
Negative
Market Momentum
-0.75
Negative
41.15
Neutral
87.24
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ANGO, the sentiment is Negative. The current price of 15.69 is above the 20-day moving average (MA) of 12.63, above the 50-day MA of 14.41, and above the 200-day MA of 12.45, indicating a bearish trend. The MACD of -0.75 indicates Negative momentum. The RSI at 41.15 is Neutral, neither overbought nor oversold. The STOCH value of 87.24 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ANGO.
AngioDynamics Risk Analysis
AngioDynamics disclosed 34 risk factors in its most recent earnings report. AngioDynamics reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
AngioDynamics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
75 Outperform | $231.88M | 21.86 | 8.78% | 1.70% | -9.62% | ― | |
72 Outperform | $281.43M | 33.62 | 14.81% | ― | 2.47% | 75.23% | |
55 Neutral | $301.74M | -8.83 | -473.55% | 0.00% | 12.93% | -219.19% | |
54 Neutral | $286.91M | -6.03 | -14.73% | ― | -18.86% | -0.63% | |
52 Neutral | $515.59M | -15.52 | -19.25% | ― | 8.20% | -0.88% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $103.21M | -4.17 | -132.62% | ― | -5.47% | 13.55% |
* Healthcare Sector Average
ANGO
AngioDynamics
12.26
-0.03
-0.24%
INFU
InfuSystem Holdings
14.13
3.68
35.22%
OSUR
Orasure Technologies
4.16
1.29
44.95%
STXS
Stereotaxis
1.03
-1.94
-65.32%
UTMD
Utah Medical Products
73.06
15.64
27.23%
SMTI
Sanara MedTech
32.84
2.49
8.20%
AngioDynamics Corporate Events
Business Operations and StrategyExecutive/Board Changes
AngioDynamics Names New CEO Amid Leadership Transition
Positive
Oct 8, 2026
On October 2, 2026, AngioDynamics’ board appointed industry veteran Eric Honroth as President and CEO and a director, effective November 2, 2026, succeeding long-time chief executive Jim Clemmer, who will retire on that date after leading th...
Business Operations and StrategyExecutive/Board ChangesFinancial Disclosures
AngioDynamics Delivers Q1 2027 Growth, Confirms Outlook
Positive
Oct 8, 2026
For the fiscal first quarter of 2027, ended August 31, 2026, AngioDynamics reported net sales of $80.9 million, up 6.9% year on year, with Med Tech revenue rising 13.2% to $39.9 million and Med Device sales edging up 1.4% to $41.0 million. GAAP gr...
Business Operations and StrategyFinancial Disclosures
AngioDynamics posts record Q4 and fiscal 2026 results
Positive
Jul 15, 2026
AngioDynamics reported record financial results for its fiscal fourth quarter and full year ended May 31, 2026, highlighting a seventh consecutive quarter of double-digit Med Tech growth and positive adjusted EBITDA. Pro forma net sales rose 8.0% ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.